Natriuretic peptides for risk stratification of patients with acute coronary syndromes

Galvani, Marcello; Ferrini, Donatella; Ottani, Filippo

doi:10.1016/j.ejheart.2004.01.006

Cited by 89 publications

(62 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These markers are becoming increasingly accepted by clinicians and laboratorians for the exclusion of HF, a disease with a high morbidity that currently affects 5 ϫ 10 6 people in the US and 10 ϫ 10 6 people in Europe and shows a high prevalence (Ͼ10%) in the elderly population (2,3 ). Recent studies have also indicated that BNP and NTproBNP may be useful as markers in other clinical settings, such as risk assessment in patients with acute coronary syndromes (4,5 ); however, full assessment of several factors, such as the biological variation in BNP (6 -8 ), its limited cardiac specificity, the various circulating forms of proBNP, and the specification of BNP and NT-proBNP assays, will be required to avoid confusion regarding interpreting results for these markers in daily practice (9 ).…”

mentioning

confidence: 99%

Analysis of Circulating Forms of proBNP and NT-proBNP in Patients with Severe Heart Failure

et al. 2008

View full text Add to dashboard Cite

show abstract

mentioning

confidence: 99%

Analysis of Circulating Forms of proBNP and NT-proBNP in Patients with Severe Heart Failure

et al. 2008

View full text Add to dashboard Cite

show abstract

“…[28] у пациентов с острым коронарным синдромом. Была обнаружена пря-мая связь между степенью дисфункции ЛЖ, величиной давления заклинивания легочной артерии и концентра-цией мозгового натрийуретического пептида, которая одновременно отражала общую вероятность риска ле-тального исхода от сердечно-сосудистых событий.…”

Section: острый коронарный синдромunclassified

Natriuretic Peptides: Role in Current Cardiology

Napalkov

2015

Annals RAMS

View full text Add to dashboard Cite

Natriuretic peptides were discovered in 50–70s of the XX century. BNP was more diagnostically and prognostically significant, as it is secreted directly into the ventricles of the heart. The studies demonstrated a high predictive value of increasing the level of BNP in acute decompensation of heart failure and in patients with chronic heart failure in a study of Val-HeFT. It was demonstrated that monitoring the level of NT-proBNP can be used for the selection of optimal therapy, affect the course and outcome of the disease, and reduce the cost of treatment. The next step in learning BNP was to undertake attempts of their use in the therapy of heart failure. Long-term therapy BNP (drug nesiritide) improved left ventricular remodelling in patients with stable heart failure. Currently the definition of the levels of BNP and NT-proBNP is used for the diagnosis and management of patients with heart failure.

show abstract

“…For example, recent data demonstrate that BNP levels are increased in patients with acute coronary syndromes and also serve as a significant prognostic factor in these patients. 32,33 …”

Section: Recognition Of Adhfmentioning

confidence: 99%

Hospitalized patients with acute decompensated heart failure: Recognition, risk stratification, and treatment review

Amin¹

2008

J. Hosp. Med.

View full text Add to dashboard Cite

Acute decompensated heart failure (ADHF) has emerged as a major healthcare problem. It causes approximately 3% of all hospitalizations in the United States, with the direct medical cost of these hospitalizations estimated at $18.8 billion per year. Early recognition, risk stratification, and evidence-based treatment are crucial in reducing the morbidity, mortality, and costs associated with this disorder. Classic signs and symptoms of ADHF, such as rales, dyspnea, and peripheral edema, may be absent at hospital presentation and, even when present, are not specific to this disorder. As a result, serum B-type natriuretic peptide level is now used to rapidly and accurately detect ADHF. Multivariate analyses have identified renal dysfunction, hypotension, advanced age, hyponatremia, and comorbidities as significant and independent mortality risk factors. Based on these factors, mortality risk can be stratified from very low to very high using published algorithms that have been validated in independent populations. Evidence-based guidelines for the treatment of ADHF are available from both the European Society of Cardiology and the Heart Failure Society of America. In general, an intravenous loop diuretic, either alone or in combination with a vasodilator, is recommended as initial therapy in patients with volume overload, depending on the patient's clinical status. Use of inotropic agents should be limited to the small subset of patients with low-output syndrome and significant hypotension. In any event, frequent monitoring of clinical response is essential, with subsequent therapy determined by this response. Finally, focused patient education during hospitalization may help reduce readmissions for ADHF. Journal of Hospital Medicine 2008;3(Suppl 6):S16-S24. V

show abstract

Natriuretic peptides for risk stratification of patients with acute coronary syndromes

Cited by 89 publications

References 29 publications

Analysis of Circulating Forms of proBNP and NT-proBNP in Patients with Severe Heart Failure

Analysis of Circulating Forms of proBNP and NT-proBNP in Patients with Severe Heart Failure

Natriuretic Peptides: Role in Current Cardiology

Hospitalized patients with acute decompensated heart failure: Recognition, risk stratification, and treatment review

Contact Info

Product

Resources

About